|
|
|
|
 |
Gourmetceuticals to Present Data from Four Studies at Experimental Biology 2008 |
| 3/26/2008 @ 6:12 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
Gourmetceuticals, LLC, a company that markets organically derived and scientifically validated ingredients for use in foods and beverages, today announced that multiple studies of Gourmetceuticals' ingredients, GLPH-1, an immune booster, and PPL-240, an antioxidant, will be presented at the Experimental Biology 2008 conference in San Diego, April 5-9, 2008 in the exhibit hall of the San Diego Convention Center. Data will be presented from clinical studies intended to highlight the clinical benefits of GLPH-1 and PPL-240 for use in functional foods and beverages.
Photoprotective Antioxidant PPL-240 Poster Presentation
April 6, 2008, 1:00 - 2:15 p.m., Abstract Title: Polypodium leucotomos extract, PPL-240, prevents solar-induced DNA damage in human peripheral blood mononuclear cells
Poster Title: Apoptosis and Cell Stress (Poster Number: A414)
Immune Booster GLPH-1 Poster Presentations
April 8, 2008, 12:15 - 1:30 p.m., Abstract Title: The presence of an alpha glucomannan polysaccharide, GLPH-1, (IF-S) activates NfkB and p38 in hMDDC
Poster Title: Chemistry and Cell Biology of Natural Products (Poster Number: A466)
April 8, 2008, 12:15 - 1:30 p.m., Abstract Title: IF-S, a phosphorylated alpha glucomannan polysaccharide, GLPH-1, induces functional human dendritic cell maturation
Poster Title: Chemistry and Cell Biology of Natural Products (Poster Number: A465)
April 8, 2008, 1:45 - 2:45 p.m., Abstract Title: Experimental animal model study of diet supplementation with phosphorylated alpha glucomannan polysaccharide, GLPH-1
Poster Title: Experimental Animal Nutrition (Poster Number: C304)
About Functional Foods
Functional foods are foods and beverages with claimed health benefits based on scientific evidence. The field of functional foods is an emerging field in the food science industry and is composed of the foods that contain scientifically validated ingredients that provide a health benefit above the benefit of the food itself. The market is growing exponentially with a projected growth from $25 billion in 2006 to $39 billion by 2011.
About Gourmetceuticals
Gourmetceuticals, LLC is a research-based culinary technology company that markets organically derived and scientifically tested ingredients for use in foods and beverages. Its ingredients, GLPH-1 and PPL-240 , can transform human and veterinary products into gourmet functional foods and are FDA approved for human and animal consumption, GRAS affirmed, kosher and meet current Good Manufacturing Practices (cGMP) as outlined by the FDA. GLPH-1 is a polysaccharide extract from botanical yeast that promotes immune health and PPL-240 is an antioxidant derived from a South American fern that has been shown clinically to reduce damage from UVA and UVB rays. Both ingredients have been subject to more than 20 clinical trials that evaluated and supported their safety and effectiveness in humans and animals. For more information, visit the Company Web site at www.gourmetceuticals.com/. |
| BioTech / BioMedical / Medical |
|
|
| |
| Friday, May 9, 2008 |
 |
|
Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference Posted 6:24 AM PST
CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Company's Common Stock and Trading in Post-split Shares Begins May 9, 2008 Posted 6:23 AM PST
Gen-Probe to Webcast Two Upcoming Investor Presentations Posted 6:21 AM PST
Cytori Reports First Celution System Revenues During the First Quarter; Provides Update on Celution System Commercialization Posted 6:15 AM PST
|
| |
| Thursday, May 8, 2008 |
 |
|
Total Training Selected as the Exclusive In-the-Box Video Training Provider for Microsoft Expression Studio 2 Posted 3:38 PM PST
Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference Posted 3:36 PM PST
Metabasis to Present at the Bank of America 2008 Health Care Conference Posted 3:29 PM PST
Ortho Organizers Introduces New Premium Product Line - O2 Select Orthodontic Instruments Posted 8:36 AM PST
Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter Posted 8:35 AM PST
DR Systems’ Integration of Mammography with PACS to Be Showcased at ACR Meeting Posted 8:05 AM PST
Nvitrogen and WARF Sign License Agreement for Human Embryonic Stem Cells Posted 8:05 AM PST
Bio-Matrix Scientific Group Identifies Near Term Revenue Sources Posted 8:02 AM PST
Aethlon Medical Releases Smallpox Related Research Data Posted 8:00 AM PST
|
| |
| Wednesday, May 7, 2008 |
 |
|
Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference Posted 2:18 PM PST
Sequenom Abstract Selected for ‘Blue Ribbon’ Designation for Presentation at ACOG Annual Meeting Posted 6:23 AM PST
Orexigen Therapeutics Announces Completion of Patient Enrollment in Phase III Clinical Program for Contrave Posted 6:23 AM PST
La Jolla Pharmaceutical Company Announces Pricing of Common Stock and Warrant Unit Offering Posted 6:21 AM PST
Invitrogen Scientists Link microRNA Sequences to Cancer Using RNA Samples from BioServe Posted 6:11 AM PST
Bio-Matrix Scientific Group, Inc. Installs Computype’s Secured Blood Bank Labeling and Identification Systems for its Adult Stem Cell Processing and Cryogenic Banking Laboratories Posted 6:09 AM PST
|
| |
| Tuesday, May 6, 2008 |
 |
|
Illumina Completes Sequencing of African Trio Posted 8:59 AM PST
Aethlon Hemopurifier Effective in Capturing West Nile Virus Posted 8:59 AM PST
TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project Posted 8:24 AM PST
Halozyme Therapeutics to Present at Upcoming Investor Conferences Posted 8:18 AM PST
NuVasive to Present at Bank of America 2008 Health Care Conference Posted 8:08 AM PST
|
| |
| Monday, May 5, 2008 |
 |
|
Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity Posted 4:29 PM PST
Biocept Launches Noninvasive Prenatal Rh(D) Diagnostic at Annual ACOG Scientific Meeting Posted 6:39 AM PST
Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca Posted 6:37 AM PST
Orexigen Therapeutics to Present at Upcoming Investor Conferences Posted 6:32 AM PST
Bio-Matrix Scientific Group, Inc. Submits Application and Quality Systems Documentation to the State of California for Tissue Bank License Posted 6:31 AM PST
Applied Biosystems & Bio-Rad Gain Gene Expression Profiling Market Share Posted 6:02 AM PST
|
| |
| Friday, May 2, 2008 |
 |
|
Aethlon Medical and Fusion Capital Execute Private Placement and Mutually Terminate March 2007 Common Stock Purchase Agreement Posted 6:12 AM PST
Somaxon Pharmaceuticals Announces Data to Be Presented at American Psychiatric Association 161st Annual Meeting Posted 6:06 AM PST
|
| |
| Thursday, May 1, 2008 |
 |
|
TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack Posted 9:47 AM PST
Cytori Begins Breast Reconstruction Study in Europe Posted 9:14 AM PST
|
| |
| Wednesday, April 30, 2008 |
 |
|
SpectraScience Announces the Sale of Colon Cancer Diagnostic Tool to Czech Republic Posted 5:13 PM PST
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May Posted 5:02 PM PST
Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference Posted 4:56 PM PST
Sequenom Announces Distribution Agreement with Invitrogen for South and Central America; Sells First MassARRAY System in Brazil Posted 4:50 PM PST
Invitrogen Announces Two-for-One Stock Split Posted 4:50 PM PST
Illumina and Genpathway Announce Partnership to Provide Whole-Genome ChIP-Sequencing Services Posted 6:53 AM PST
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences Posted 6:41 AM PST
Cytori Closes 2nd Half of $12 Million Equity Agreement with Green Hospital Supply Posted 6:39 AM PST
International Stem Cell Corporation Obtains Exclusive Rights in the US and Canada to Distribute Approved Human Skin Model for Toxicity Testing Posted 6:17 AM PST
|
| |
| Tuesday, April 29, 2008 |
 |
|
Illumina to Present at Upcoming Investment Conferences in May Posted 6:12 AM PST
|
| |
| Monday, April 28, 2008 |
 |
|
Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration Posted 2:38 PM PST
NuVasive to Present at Morgan Stanley Global Healthcare Unplugged Conference Posted 6:22 AM PST
Metabasis Therapeutics Announces Positive Results in the Phase 2a Clinical Trial for MB07803, Its Product Candidate for the Treatment of Type 2 Diabetes Posted 6:12 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5.000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|